Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

PartnershipIdefirixPositive

AI Analysis

Summary

Hansa Biopharma closed a €115 million licensing deal with SERB Pharmaceuticals for commercialization rights to Idefirix in Europe, UK, Switzerland, and the MENA region. The transaction strengthens Hansa's financial position and supports its US launch plans.

Financial Highlights

Revenue

€115 million

Outcome Details

Licensing transaction closed for €115 million

Importance:7/10

Sentiment:

0.70

licensingpartnershipEuropeMENAcommercializationtransplantation

Related Companies

$HNSA.ST

Read the original article

Published by PR Newswire Pharma on July 1, 2026 1:24 PM

Read Original